Global Addison’s Disease Market Clinical Review and Research Report 2018
- sagar joshi
- Nov 19, 2018
- 1 min read
Global Addison’s Disease Market is expected to grow significantly over the forecast period. It is anticipated that the market held a valuation of USD 168 million in 2017 and is projected to grow at a CAGR of 10.4% over the forecast period. Addison’s disease is a disorder which occurs when the body produces scarce amounts of specific hormones produced by the adrenal glands.
Pfizer Inc., Boehringer Ingelheim International GmbH, Shire, Tocris Bioscience, GlaxoSmithKline plc, Merck KGaA, Lupin Pharmaceuticals, Inc., Abbott, Amgen Limited & Amgen Ireland Limited, Bayer AG, Biogen, Eli Lilly and Company, Novartis AG, Diurnal, Switzer Life science Pvt. Ltd. are some of the key players in the global Addison’s disease market.
However, lack of awareness and inability to diagnose the disease in early stages can hamper the market growth over the forecast period.
Browse Complete Premium Research Report Enabled with Respective Tables and Figures at https://www.marketresearchfuture.com/reports/addison-s-disease-market-6628
Global Addison’s Disease Market has been segmented into diagnosis, treatment and end user.
The market, on the basis of diagnosis, has been segmented into laboratory tests and imaging tests. Laboratory tests have been further segmented into blood tests, ACTH stimulation tests, insulin-induced hypoglycemia test, and other tests. Blood tests are expected to hold the largest market share owing to their high effectiveness to diagnose the disease and preference among the physicians. ACTH stimulation test is expected to be the fastest growing market due to the low cost of the diagnosis method. Imaging tests have been segmented into chest radiography and CT scan.
Comments